Mitigation

Datadobi Now Available in Amazon Web Services (AWS) Marketplace

Retrieved on: 
Monday, June 12, 2023
Data management, Product marketing, Metadata, Amazon Web Services, Assured Compliance Assessment Solution, Mitigation, Sale, Organization, Cost, Risk, AWS, News, Tutoring, Online shopping

LEUVEN, Belgium, June 12, 2023 /PRNewswire-PRWeb/ -- Datadobi, a global leader in unstructured data management, today announced its StorageMAP Assess solution and StorageMAP Unstructured Data Management software is now available in AWS Marketplace, a digital catalog with thousands of software listings from independent software vendors that make it easy to find, test, buy, and deploy software that runs on Amazon Web Services (AWS).

Key Points: 
  • Datadobi will offer two versions of its StorageMAP in AWS Marketplace: StorageMAP Assess, which provides insight and analysis of unstructured data environments, and StorageMAP Unstructured Data Management, which allows users to take action on that data.
  • The availability of Datadobi StorageMAP Assess solution and Datadobi StorageMAP Unstructured Data Management software in AWS Marketplace is great news for Datadobi's channel partners.
  • Ultimately, the addition of Datadobi StorageMAP Assess solution and Datadobi StorageMAP Unstructured Data Management software to AWS Marketplace strengthens Datadobi's channel partner ecosystem by providing more opportunities to sell and provide additional value to their customers.
  • Find StorageMAP Assess in AWS Marketplace here: https://aws.amazon.com/marketplace/pp/prodview-hngbknqgaxjbq and StorageMAP Unstructured Data Management here: https://aws.amazon.com/marketplace/pp/prodview-5sy467mv6fspk .

SolasAI Adds Top-Tier Advisors To Bolster Responsible AI Leadership & Model Risk Management

Retrieved on: 
Wednesday, June 7, 2023
Cloud, HSBC, CFPB, Gartner, EY, Hughes, Risk management, Record, CMO, Central Waqf Council, Entrepreneurship, Consumer Financial Protection Bureau, Credit card, Explainable artificial intelligence, Cisco, Algorithm, Consumer, Growth, GTM, AI, Nike, NTT Data, NTT, Bias, Discover Financial, Responsibility, Mitigation, Management, Medical device

PHILADELPHIA, June 7, 2023 /PRNewswire-PRWeb/ -- SolasAI, the leader in market-proven algorithmic fairness AI software, today announced the addition of five industry leaders to its Board of Advisors. The advisors have expertise in important drivers shaping the evolution of Responsible AI from fairness and regulatory compliance to innovation and business value.

Key Points: 
  • The advisors have expertise in important drivers shaping the evolution of Responsible AI from fairness and regulatory compliance to innovation and business value.
  • The new advisory board will propel SolasAI's mission to continue pioneering Responsible AI solutions optimized for real-world adoption, more equitable societal outcomes, and regulatory compliance.
  • "Our advisors bring Responsible AI & regulatory domain expertise to the table as well as proven track records of growth, risk management, and innovation,– said Larry Bradley, CEO of SolasAI.
  • ‒Their backgrounds align strongly with our proactive approach to Responsible AI and rapid value realization.

Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023

Retrieved on: 
Wednesday, May 31, 2023
Sodium oxybate, Orphan, Abstract, AASM, Central nervous system, American Academy of Sleep Medicine, Cataplexy, Doctor of Pharmacy, Sleep, Senior, Enuresis, Mitigation, EDS, Narcolepsy, Sleep Research Society, Food and Drug Administration, Weight loss, Severe cutaneous adverse reactions, American Academy, CIII, Approximation error, Vomiting, Incidence, Dizziness, Patient, Nausea, Poster, FDA, Health, Headache, Food, Pharmaceutical industry

DUBLIN, May 31, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced new data supporting the clinical profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) and patient preference for a once-nightly oxybate in 12 abstracts, including six oral presentations, at SLEEP 2023, the 37th annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society, being held from June 3-7, 2023 in Indianapolis.

Key Points: 
  • DUBLIN, May 31, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced new data supporting the clinical profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) and patient preference for a once-nightly oxybate in 12 abstracts, including six oral presentations, at SLEEP 2023, the 37th annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society, being held from June 3-7, 2023 in Indianapolis.
  • LUMRYZ was granted U.S. Food and Drug Administration (FDA) approval in May 2023, and is the first and only FDA approved once-at-bedtime oxybate for people living with narcolepsy.
  • “We are thrilled to attend SLEEP 2023 and present a broad range of data further supporting the clinical value proposition of LUMRYZ as a once-nightly option to manage EDS and cataplexy in narcolepsy, including data from our RESTORE and REST-ON trials,” said Jennifer Gudeman, PharmD, Senior Vice President, Medical and Clinical Affairs of Avadel.
  • LUMRYZ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy called the LUMRYZ REMS.

Travelers Institute® to Host Cybersecurity Symposium in Charlotte, North Carolina

Retrieved on: 
Tuesday, May 23, 2023
Technology, Professional Services, Insurance, Security, The Travelers Companies, Education, Public policy, Culture, Cybersecurity and Infrastructure Security Agency, Traveler, Mitigation, Organization, Gambling, Small business, TRV, Conference, NYSE, Computer security, Risk management

The Travelers Institute , the public policy division of The Travelers Companies, Inc. (NYSE: TRV ), will host its in-person Cyber: Prepare, Prevent, Mitigate, Restore® symposium today, May 23, in Charlotte.

Key Points: 
  • The Travelers Institute , the public policy division of The Travelers Companies, Inc. (NYSE: TRV ), will host its in-person Cyber: Prepare, Prevent, Mitigate, Restore® symposium today, May 23, in Charlotte.
  • “As cyberattacks become more frequent and sophisticated, it’s essential that companies make a concerted effort to manage these threats,” said Joan Woodward, President of the Travelers Institute and Executive Vice President of Public Policy at Travelers.
  • “A recent Travelers survey found that only 29% of Charlotte businesses are cyber conscious.
  • Other speakers include Tim Francis, Vice President, Enterprise Cyber Lead at Travelers, and Jennifer Coughlin, Partner at Mullen Coughlin.

FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder

Retrieved on: 
Tuesday, May 23, 2023
Injection, REMS, Substance Abuse, Buprenorphine, Drug overdose, Education, Mitigation, Molina Healthcare, Senior counsel, Opioid use disorder, Skin, Substance Abuse and Mental Health Services Administration, Constipation, OUD, Urinary tract infection, Insomnia, Patient, Risk, Nausea, Drug, Diagnosis, FDA, Headache, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Factitious disorder, Counterfeit, Food, Safety, SAMHSA, Pharmaceutical industry, Vaccine

"Buprenorphine is an important treatment option for opioid use disorder.

Key Points: 
  • "Buprenorphine is an important treatment option for opioid use disorder.
  • Today's approval expands dosing options and provides people with opioid use disorder a greater opportunity to sustain long-term recovery," said FDA Commissioner Robert M. Califf, M.D.
  • After an initial test dose of transmucosal buprenorphine, patients were randomized to treatment with Brixadi plus a sublingual placebo, or active sublingual buprenorphine plus placebo injections.
  • A response to treatment was measured by urine drug screening and self-reporting of illicit opioid use during the treatment period.

Braeburn's BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection (CIII) Receives FDA Approval for Moderate to Severe Opioid Use Disorder

Retrieved on: 
Tuesday, May 23, 2023
REMS, Mitigation, Pharmacy, Buprenorphine, Senior counsel, Health care, Opioid use disorder, OUD, SL, CIII, Heroin, Patient, Risk, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Vaccine, Pharmaceutical industry

PLYMOUTH MEETING, Pa., May 23, 2023 /PRNewswire/ -- Braeburn announces that the U.S. Food and Drug Administration (FDA) has approved BRIXADI (buprenorphine) extended-release injection for subcutaneous use (CIII), a new weekly and monthly medication for moderate to severe opioid use disorder (OUD) in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with a transmucosal buprenorphine-containing product. BRIXADI should be used as part of a complete treatment plan that includes counseling and psychosocial support. BRIXADI is to be administered only by healthcare providers in a healthcare setting and will be available in the U.S. in September 2023.

Key Points: 
  • Patients currently on a transmucosal buprenorphine-containing product can be switched to an equivalent dose of BRIXADI Weekly or Monthly.
  • BRIXADI is the first and only weekly and monthly subcutaneous injection for moderate to severe OUD and is the only buprenorphine injectable that utilizes FluidCrystal®* Injection Depot Technology.
  • "Today's FDA approval of BRIXADI is a significant step forward in the fight against OUD," said Mike Derkacz, President and CEO of Braeburn.
  • Additional medication options for opioid use disorder will support healthcare providers in addressing the needs of their patients with opioid use disorder."

New digital accessibility metrics launched by Lumar, a leading website intelligence and SEO platform

Retrieved on: 
Wednesday, May 17, 2023
URL, Marketing, Disability, Intelligence, World Wide Web Consortium, Mitigation, SEO, Organization, AAA, QA, WCAG, Service-level agreement, UX, WHO, Health, AA, World Health Organization, Online shopping, Publishing, Retail

NEW YORK, and LONDON, May 17, 2023 /PRNewswire/ -- Lumar, a leader in the website intelligence and technical SEO space, today announced the launch of new digital accessibility metrics and accessibility health scores within its website intelligence platform.

Key Points: 
  • NEW YORK, and LONDON, May 17, 2023 /PRNewswire/ -- Lumar, a leader in the website intelligence and technical SEO space, today announced the launch of new digital accessibility metrics and accessibility health scores within its website intelligence platform .
  • Powered by Lumar's ultra-fast proprietary website crawler and the leading digital accessibility library, axe®, the new website accessibility reports further expand Lumar's website intelligence offering beyond its origins as a major player in the technical SEO space.
  • Users can now examine technical SEO and website accessibility issues within a single platform.
  • With Lumar, digital teams can:
    Access a single source of truth for website intelligence: Technical SEO, accessibility, and other crucial website health issues can be viewed on a single platform.

New digital accessibility metrics launched by Lumar, a leading website intelligence and SEO platform

Retrieved on: 
Wednesday, May 17, 2023
URL, Marketing, Disability, Intelligence, World Wide Web Consortium, Mitigation, SEO, Organization, AAA, QA, WCAG, Service-level agreement, UX, WHO, Health, AA, World Health Organization, Online shopping, Publishing, Retail

NEW YORK, and LONDON, May 17, 2023 /PRNewswire/ -- Lumar, a leader in the website intelligence and technical SEO space, today announced the launch of new digital accessibility metrics and accessibility health scores within its website intelligence platform.

Key Points: 
  • NEW YORK, and LONDON, May 17, 2023 /PRNewswire/ -- Lumar, a leader in the website intelligence and technical SEO space, today announced the launch of new digital accessibility metrics and accessibility health scores within its website intelligence platform .
  • Powered by Lumar's ultra-fast proprietary website crawler and the leading digital accessibility library, axe®, the new website accessibility reports further expand Lumar's website intelligence offering beyond its origins as a major player in the technical SEO space.
  • Users can now examine technical SEO and website accessibility issues within a single platform.
  • With Lumar, digital teams can:
    Access a single source of truth for website intelligence: Technical SEO, accessibility, and other crucial website health issues can be viewed on a single platform.

Olatec Therapeutics Announces the Completion of First Dose Cohort in an Innovative Trial Investigating Olatec’s NLRP3 Inhibitor Dapansutrile and Merck’s Keytruda® in Patients with Advanced Refractory Melanoma at Duke Cancer Institute

Retrieved on: 
Tuesday, May 16, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Oncology, DREAM, Human, PI, Frontiers, CSO, NLRP3, Immunotherapy, PFS, Mitigation, JCI, Publication, Patient, Melanoma, Cancer, Mouse, Merck, Neoplasm, Principal, PD-1, Pembrolizumab, Therapy, Rationale, ORR, Safety, Disease, Pharmaceutical industry, Vaccine, PNAS, Immunology

This trial is evaluating the combination treatment of Olatec’s dapansutrile, an NLRP3 inhibitor, and pembrolizumab (Keytruda®) in patients with PD-1 refractory advanced melanoma.

Key Points: 
  • This trial is evaluating the combination treatment of Olatec’s dapansutrile, an NLRP3 inhibitor, and pembrolizumab (Keytruda®) in patients with PD-1 refractory advanced melanoma.
  • The study is being led by Principal Investigator (PI), April Salama MD, Head of the Melanoma Program at The Duke Cancer Research Institute and supported by Olatec and Merck & Co., Inc. (Merck).
  • The aim of the DREAM Trial is to address the unmet need in patients with PD-1 refractory advanced melanoma.
  • Immunotherapy with immune checkpoint inhibitors (e.g., anti-PD-1 therapies) has transformed the treatment of melanoma, significantly improving the outcome of patients with this disease.

Tokyo International Fire and Safety Exhibition 2023

Retrieved on: 
Monday, May 15, 2023
Learning, Emergency service, Exhibition, URL, Tokyo Big Sight, Electricity, Service, NPO “Digital Television Systems”, Seminar, Fire, EVS, Organization, Disaster, Earthquake, Tokyo Fire Department, Executive Committee, Communication, Information system, Emergency, Tsunami, Mitigation, Tunnel, Nursing, Nightclub, Entertainment

TOKYO, May 15, 2023 - (JCN Newswire) - Tokyo Fire Department, Tokyo Big Sight Inc. and Tokyo International Fire and Safety Exhibition 2023 Executive Committee will hold the "Tokyo International Fire and Safety Exhibition 2023" at Tokyo Big Sight (East Halls 5, 6 and 7, Outdoor Exhibition Area, Offshore of Ariake-Nishi Port Park) from Thursday, June 15 to Sunday, June 18, 2023.

Key Points: 
  • TOKYO, May 15, 2023 - (JCN Newswire) - Tokyo Fire Department, Tokyo Big Sight Inc. and Tokyo International Fire and Safety Exhibition 2023 Executive Committee will hold the "Tokyo International Fire and Safety Exhibition 2023" at Tokyo Big Sight (East Halls 5, 6 and 7, Outdoor Exhibition Area, Offshore of Ariake-Nishi Port Park) from Thursday, June 15 to Sunday, June 18, 2023.
  • "Tokyo International Fire and Safety Exhibition 2023" is one of the largest fire and disaster prevention exhibitions in Japan, held once every five years.
  • + Outdoor Exhibition Area with impressive firefighting performances, and where kid's can have fun as they learn
    At the Outdoor Exhibition Area, in addition to corporate product exhibits, the Tokyo Fire Department will present powerful firefighting performances.
  • Various materials such as logos and photos from the previous exhibition can be downloaded from the URL below.